BioXcel Therapeutics (BTAI) Prices 4M Share Common Offering at $50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Pre-Open Stock Movers 07/28: (KODK) (LUMO) (CVLT) Higher; (ALNA) (EDU) (TSLA) Lower (more...)
July 28, 2020 9:25 AM EDTToday's Pre-Open Stock Movers:
Kodak (NYSE: KODK) 229% HIGHER; $765 million Defense Production Act loan for drug ingredient push.
Lumos Pharma, Inc. (NASDAQ: LUMO) 21.4% HIGHER; announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck (NYSE: MRK), known as MSD outside the United States and Canada.
Commvault Systems (NASDAQ: CVLT) 13.5% HIGHER; reported Q1 EPS of $0.51,... More
After-Hours Stock Movers 07/27: (LUMO) (AMKR) (VCRA) Higher; (ALNA) (NXPI) (BTAI) Lower (more...)
July 27, 2020 5:59 PM EDTToday's After-Hours Stock Movers:
Lumos Pharma, Inc. (NASDAQ: LUMO) 21.4% HIGHER; announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck (NYSE: MRK), known as MSD outside the United States and Canada.
Amkor Technology (NASDAQ: AMKR) 11.5% HIGHER; reported Q2 EPS of $0.23, $0.26 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.17 billion versus the consensus estimate of $1.05 billion. Amkor Technology sees Q3 2020 EPS of... More
BioXcel Therapeutics (BTAI) Announces $200M Proposed Public Offering of Common Stoc
July 27, 2020 4:21 PM EDTBioXcel Therapeutics, Inc. (BTI or the Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. In addition, certain selling stockholders expect to grant the underwriters a 30-day option to... More
